2025
Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice
Sharma L, Singh R, Ngeow C, van der Geest R, Duray A, Tolman N, McVerry B, Dela Cruz C, Alcorn J, Bain W, Robinson K. Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice. Physiological Reports 2025, 13: e70232. PMID: 39921246, PMCID: PMC11805821, DOI: 10.14814/phy2.70232.Peer-Reviewed Original ResearchConceptsMurine model of influenzaIL-6 deletionMRSA pneumoniaModel of influenzaInflammatory cell recruitmentIL-6Interferon-stimulated genesMurine modelCell recruitmentJAK inhibitionElevated levels of IL-6Tissue injuryLevels of IL-6IL-6 deficiencyJAK inhibitor baricitinibSuppression of cytokinesLimit tissue injuryLung tissue injurySecondary bacterial infectionInfluenza infectionJAK/STAT signaling pathwayBaricitinib treatmentInhibitory therapyClinical efficacyBacterial burden
2021
JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis
Walz L, Cohen AJ, Rebaza AP, Vanchieri J, Slade MD, Dela Cruz CS, Sharma L. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis. BMC Infectious Diseases 2021, 21: 47. PMID: 33430799, PMCID: PMC7797881, DOI: 10.1186/s12879-020-05730-z.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 Drug TreatmentHumansInterferon Type IJanus Kinase InhibitorsSARS-CoV-2Treatment OutcomeConceptsCOVID-19 patientsType I interferonOdds of mortalityPositive clinical outcomesClinical outcomesI interferonICU admissionExcessive cytokine releaseType I interferon treatmentStandard treatment groupOdds of dischargeFavorable clinical outcomeNon-randomized trialsJanus kinase inhibitorSearch of MEDLINETerms of mortalityKinase inhibitor treatmentHospital dischargeCytokine releaseInterferon treatmentPotential antiviral candidatesNovel therapiesTreatment outcomesTreatment groupsAntiviral candidates
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply